These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 17636697)

  • 1. WITHDRAWN: Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy.
    Airey M; Bennett C; Nicolucci A; Williams R
    Cochrane Database Syst Rev; 1996 Apr; (1):CD002182. PubMed ID: 17636697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy.
    Airey M; Bennett C; Nicolucci A; Williams R
    Cochrane Database Syst Rev; 2000; 1996(2):CD002182. PubMed ID: 10796870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. The Italian Study Group. The St. Vincent Declaration.
    Nicolucci A; Carinci F; Cavaliere D; Scorpiglione N; Belfiglio M; Labbrozzi D; Mari E; Benedetti MM; Tognoni G; Liberati A
    Diabet Med; 1996 Dec; 13(12):1017-26. PubMed ID: 8973882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldose reductase inhibitors for the treatment of diabetic polyneuropathy.
    Chalk C; Benstead TJ; Moore F
    Cochrane Database Syst Rev; 2007 Oct; 2007(4):CD004572. PubMed ID: 17943821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study.
    Hotta N; Toyota T; Matsuoka K; Shigeta Y; Kikkawa R; Kaneko T; Takahashi A; Sugimura K; Koike Y; Ishii J; Sakamoto N;
    Diabetes Care; 2001 Oct; 24(10):1776-82. PubMed ID: 11574441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: A randomized double-blind placebo-controlled study in Japan.
    Sekiguchi K; Kohara N; Baba M; Komori T; Naito Y; Imai T; Satoh J; Yamaguchi Y; Hamatani T;
    J Diabetes Investig; 2019 Mar; 10(2):466-474. PubMed ID: 29975462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial.
    Hotta N; Akanuma Y; Kawamori R; Matsuoka K; Oka Y; Shichiri M; Toyota T; Nakashima M; Yoshimura I; Sakamoto N; Shigeta Y
    Diabetes Care; 2006 Jul; 29(7):1538-44. PubMed ID: 16801576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldose reductase inhibition in the treatment of diabetic neuropathy: where are we in 2004?
    Gabbay KH
    Curr Diab Rep; 2004 Dec; 4(6):405-8. PubMed ID: 15539002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review.
    Schemmel KE; Padiyara RS; D'Souza JJ
    J Diabetes Complications; 2010; 24(5):354-60. PubMed ID: 19748287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial.
    Sundkvist G; Armstrong FM; Bradbury JE; Chaplin C; Ellis SH; Owens DR; Rosén I; Sönksen P
    J Diabetes Complications; 1992; 6(2):123-30. PubMed ID: 1611136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement].
    Shimada H; Miki T; Kyogoku I; Kawagishi T; Inaba M; Okuno Y; Nishizawa Y; Morii H
    No To Shinkei; 1998 Sep; 50(9):817-20. PubMed ID: 9789304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of tolrestat in the treatment of diabetic peripheral neuropathy. A meta-analysis of individual patient data.
    Nicolucci A; Carinci F; Graepel JG; Hohman TC; Ferris F; Lachin JM
    Diabetes Care; 1996 Oct; 19(10):1091-6. PubMed ID: 8886554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan.
    Hotta N; Sakamoto N; Shigeta Y; Kikkawa R; Goto Y
    J Diabetes Complications; 1996; 10(3):168-72. PubMed ID: 8807467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldose reductase inhibitors in the treatment of diabetic neuropathy. A review of the rationale and clinical evidence.
    Masson EA; Boulton AJ
    Drugs; 1990 Feb; 39(2):190-202. PubMed ID: 2109678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
    Shindo H; Tawata M; Aida K; Onaya T
    J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil, in symptomatic diabetic neuropathy.
    Lewin IG; O'Brien IA; Morgan MH; Corrall RJ
    Diabetologia; 1984 Jun; 26(6):445-8. PubMed ID: 6432615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy.
    Nakayama M; Nakamura J; Hamada Y; Chaya S; Mizubayashi R; Yasuda Y; Kamiya H; Koh N; Hotta N
    Diabetes Care; 2001 Jun; 24(6):1093-8. PubMed ID: 11375376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes.
    Jaspan JB; Towle VL; Maselli R; Herold K
    Metabolism; 1986 Apr; 35(4 Suppl 1):83-92. PubMed ID: 3083212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trials of sorbinil on nerve function.
    Pfeifer MA
    Metabolism; 1986 Apr; 35(4 Suppl 1):78-82. PubMed ID: 3083211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 12-month randomized controlled study of the aldose reductase inhibitor ponalrestat in patients with chronic symptomatic diabetic neuropathy.
    Krentz AJ; Honigsberger L; Ellis SH; Hardman M; Nattrass M
    Diabet Med; 1992 Jun; 9(5):463-8. PubMed ID: 1611835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.